Approvable Letter Issued on Urinary Carcinoma Therapy

October 22 2007

Indevus Pharmaceuticals, Inc., of Lexington, Mass., announced that it has received an approvable letter for Valstar (valrubicin solution), the only FDA-approved product for therapy of bacillus Calmette-Guérin-refractory carcinoma in situ of the urinary bladder.

<< Return to Approvable Letter Issued on Urinary Carcinoma Therapy

Your Email Address:

Recipient(s) Email Address:

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Include a message (optional):

The e-mail address(es) that you supply to use this service will only be used to send the requested article.